Articles with keyword mutation
-
Expanding the clinical uses of ctDNA
A.S. Zhabina
cfDNA, mutation, resistance, disease monitoring.
-
Prognostic significance of longitudinal evaluation on egfr mutant ctdna during tki treatment in nsclc
F.V. Moiseenko, N.M. Volkov, A.S. Zhabina, M.L. Stepanova, N.A. Rjsev, V.V. Klimenko, A.V. Myslik, E.V. Artemieva, N.H. Abduloeva, V.V. Egorenkov, V.M. Moiseyenko
mutations, EGFR, tumor, ctDNA, therapy.
-
MOLECULAR TARGETS IN LUNG CANCER: CURRENT STATUS
E.N. Imyanitov
lung cancer, mutation, smoking, tumor, inhibitor
-
Advances in fundamental oncology: the year 2020 update
E.N. Imyanitov
Genes, mutations, gene expression, predictive markers.
-
Advances in fundamental oncology: the year 2022 update
E.N. Imyanitov
Genes, mutations, gene expression, predictive markers.
-
Advances in fundamental oncology: the year 2021 update
E.N. Imyanitov
Genes, mutations, gene expression, predictive markers
-
Relationship between molecular genetic and clinical and morphological parameters in patients with stage i–iiia non-small cell lung cancer
А.М. Kazakov, К.К. Laktionov, К.А. Sarantseva, М.G. Gordiev
targeted sequencing, somatic mutations, non-small cell lung cancer
-
The role of liquid biopsy in the choice of tactics For the treatment of non-small cell lung cancer
K.K. Laktionov, A.M. Kazakov, K.A. Sarantseva, E.V. Reutova, A.L. Arzumanyan, N.M. Moskalyuk
non-small cell lung cancer, fluid biopsy, mutation profile, minimal residual disease
-
The role of using circulating tumor dna in the treatment of disseminated patients with non-small cell lung cancer
К.К. Laktionov, А.М. Kazakov, М.G. Gordiev
circulating tumor DNA, tumor mutation burden, non-small cell lung cancer, immunotherapy.
-
Multifactorial analysis of the dependence of prescribed diagnostic test systems and purchased targeted drugs on the example of lung adenocarcinoma in St.P.
D.D. Zelikova, D.S. Yurochkin, S.E. Erdni-Garyaev, A.A. Leshkevich, Z.M. Golant, D.A. Chagin, N.M. Volkov, F.V. Moiseenko, V.M. Moiseenko
Non-small cell lung cancer, EGFR mutation, drug provision, targeted therapy, molecular genetic test systems.
-
Biomarkers predicting the effect of immunotherapy: what you need to know in practice?
A.M. Konstantinova
immunotherapy, CTLA-4, PD-1, PD-L1, microsatellite instability, mutation burden, tumor-infiltrating lymphocytes, biomarkers, efficacy.
-
Assessment of the frequency of BRCA1/2 muta ions detection by means of PCR in State Budgetary Healthcare Institution «Saint-Petersburg clinical scientific and practical center for specialised types of medical care (oncological) named after N.P. Napalkov»
N.K. Abduloeva, O.A. Skripko, M.V. Scriabin, F.V. Moiseenko, A.S. Zhabina, V.V. Yegorenkov, N.G. Nikulushkin, N.M. Volkov, K.N. Kazakova, S.K. Kaitova, K.V. Shelekhova, V.M. Moiseenko
1/2 germinal mutation, polymerase chain reaction, breast cancer, ovarian cancer, Russian Federation, metastatic prostate cancer (MRC), pancreatic cancer (RPlC).
-
BIOLOGY CHRACTERISTICS IN UROLOGICAL CANCERS DEVELOPEMENT
P.S. Borisov, R.V. Orlova, E.E. Topuzov
urothelial carcinoma, muscle invasive bladder cancer (MIBC), non-muscle invasive bladder cancer (NMBC), FGFR3, TP53, oncogene, mutation load, genetic profiling.
-
MOLECULAR-ORIENTED AND PRECISION CANCER THERAPY – THE PRESENT AND FUTURE ASPECTS
D.B. Korman
cancer, molecular-oriented drugs, precision therapy, sequencing DNA, tumor-associated mutations, tumor-type agnostic therapy.
-
Fundamental oncology in 2015: a review of the most interesting discoveries
E.N. Imyanitov
сancer immunotherapy, fundamental oncology, microsatellite instability, acquired cancer resistance, circulating tumor DNA, cancer hormonotherapy, KRAS mutation
-
Clinical experience of afatinib application In non-cell lung cancer of lung. Ii line of therapy
L.M. Kogoniya, E.V. Markarova, G.A. Stashuk, V.E. Shikina
lung cancer, adenocarcinoma, non-small cell lung cancer, EGFR mutation, chemotherapy, targeted therapy, efficacy, elderly, side effects
-
EVOLUTION OF SCREENING FOR PROSTATE CANCER
A.I. Novikov
prostate cancer, screening, prostate-specific antigen (PSA), prostate health index, multiparameter magnetic-resonance tomography (mpMRI), biomarkers (Select MDX, HOXX6, DLX1), genetic mutations (BRCA1/2, HOXB13).
-
Neurooncology
D.E. Matskо, M.V. Matsko, E.N. Imyanitov
classification of CNS tumors, the degree of malignancy of the central nervous system tumors, molecular genetics, mutations in the gene IDH1/2, the co-deletion 1p19q, neurooncology